|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MARCH9 |
Gene summary for MARCH9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MARCH9 | Gene ID | 92979 |
| Gene name | membrane associated ring-CH-type finger 9 | |
| Gene Alias | MARCH-IX | |
| Cytomap | 12q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q86YJ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 92979 | MARCH9 | C21 | Human | Oral cavity | OSCC | 2.54e-02 | 1.32e-01 | 0.2678 |
| 92979 | MARCH9 | C30 | Human | Oral cavity | OSCC | 1.98e-13 | 6.57e-01 | 0.3055 |
| 92979 | MARCH9 | C43 | Human | Oral cavity | OSCC | 8.29e-04 | 1.79e-01 | 0.1704 |
| 92979 | MARCH9 | C46 | Human | Oral cavity | OSCC | 2.57e-02 | 1.61e-01 | 0.1673 |
| 92979 | MARCH9 | C08 | Human | Oral cavity | OSCC | 4.32e-30 | 5.40e-01 | 0.1919 |
| 92979 | MARCH9 | LN46 | Human | Oral cavity | OSCC | 1.95e-02 | 2.54e-01 | 0.1666 |
| 92979 | MARCH9 | SYSMH1 | Human | Oral cavity | OSCC | 4.49e-16 | 3.41e-01 | 0.1127 |
| 92979 | MARCH9 | SYSMH2 | Human | Oral cavity | OSCC | 1.37e-13 | 3.73e-01 | 0.2326 |
| 92979 | MARCH9 | SYSMH3 | Human | Oral cavity | OSCC | 3.45e-14 | 4.04e-01 | 0.2442 |
| 92979 | MARCH9 | SYSMH4 | Human | Oral cavity | OSCC | 4.09e-06 | 1.50e-01 | 0.1226 |
| 92979 | MARCH9 | SYSMH6 | Human | Oral cavity | OSCC | 1.10e-05 | 1.43e-01 | 0.1275 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MARCH9 | insertion | Nonsense_Mutation | novel | c.704_705insCCCCTTTTACAAACGAGGACACTGATGCACAAAGATTTGAAA | p.Ile235_Gly236insProPheTyrLysArgGlyHisTerCysThrLysIleTerLys | p.I235_G236insPFYKRGH*CTKI*K | Q86YJ5 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| MARCH9 | insertion | Frame_Shift_Ins | novel | c.1024_1025insCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGC | p.Arg342ThrfsTer76 | p.R342Tfs*76 | Q86YJ5 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MARCH9 | SNV | Missense_Mutation | c.878N>G | p.Ser293Cys | p.S293C | Q86YJ5 | protein_coding | deleterious(0.01) | benign(0.213) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MARCH9 | insertion | Nonsense_Mutation | novel | c.885_886insTAGATCT | p.Thr296Ter | p.T296* | Q86YJ5 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| MARCH9 | SNV | Missense_Mutation | rs199943129 | c.911N>A | p.Arg304His | p.R304H | Q86YJ5 | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MARCH9 | SNV | Missense_Mutation | rs146323526 | c.989N>A | p.Arg330His | p.R330H | Q86YJ5 | protein_coding | tolerated(0.11) | benign(0.058) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| MARCH9 | SNV | Missense_Mutation | rs768854594 | c.541N>A | p.Glu181Lys | p.E181K | Q86YJ5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MARCH9 | SNV | Missense_Mutation | c.986N>T | p.Ala329Val | p.A329V | Q86YJ5 | protein_coding | tolerated(0.29) | benign(0.012) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MARCH9 | SNV | Missense_Mutation | novel | c.824N>A | p.Gly275Glu | p.G275E | Q86YJ5 | protein_coding | tolerated(0.96) | benign(0.05) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MARCH9 | SNV | Missense_Mutation | rs373196172 | c.866N>T | p.Thr289Met | p.T289M | Q86YJ5 | protein_coding | tolerated(0.27) | possibly_damaging(0.54) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |